article Open AccessTop 1% cited

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

Clinical Pharmacology & Therapeutics · 2017 · Vol. 102(3) · pp. 397–404

JA Johnson✉(University of Florida)KE Caudle(St. Jude Children's Research Hospital)Li Gong(Stanford University)Michelle Whirl‐Carrillo(Stanford University)Catherine M. SteinStuart A. Scott(Icahn School of Medicine at Mount Sinai)MT Lee(National Center for Genome Resources)Brian F. Gage(Washington University in St. Louis)SE Kimmel(University of Pennsylvania)Minoli A. Perera(University of Chicago)JL Anderson(University of Utah)Munir Pirmohamed(Personalis (United States))Teri E. Klein(Stanford University)NA Limdi(University of Alabama at Birmingham)Larisa H. Cavallari(University of Florida)Mia Wadelius(Science for Life Laboratory)

View via DOI Full-text PDF

Abstract

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

Pharmacogenetics and Drug Metabolism Hormonal Regulation and Hypertension Inflammatory mediators and NSAID effectsPharmacogeneticsDosingWarfarinMedicineGuidelineVKORC1CYP2C9PharmacologyInternal medicineBiology

MeSH terms

Cytochrome P450 Family 4AdultAnticoagulantsChildDose-Response Relationship, DrugGenotypeHumansPharmacogeneticsWarfarinPractice Guidelines as TopicVitamin K Epoxide ReductasesCytochrome P-450 CYP2C9